Jitendra Wadhane - Mar 24, 2023 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Role
Chief Accounting Officer
Signature
/s/ Jitendra Wadhane
Stock symbol
PYXS
Transactions as of
Mar 24, 2023
Transactions value $
$0
Form type
4
Date filed
3/28/2023, 04:45 PM
Previous filing
Aug 9, 2022
Next filing
Sep 8, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PYXS Common Stock Award $0 +29.4K +33.16% $0.00 118K Mar 24, 2023 Direct F1
transaction PYXS Common Stock Award $0 +45K +103.1% $0.00 88.6K Mar 24, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PYXS Stock Option (Right to buy) Disposed to Issuer -157K -100% 0 Mar 24, 2023 Common Stock 157K $8.71 Direct F3, F4
transaction PYXS Stock Option (Right to buy) Award +157K 157K Mar 24, 2023 Common Stock 157K $2.21 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
F2 Represents restricted stock units that vest 25% on August 3, 2023, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
F3 In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
F4 These stock options vested 25% on August 23, 2022, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.